Question normal

Drs. Verhamme, Bauersachs and Davidson,

Thank you very much for participating in this Journal Club.

In the results, you talk about the number needed to treat to prevent one fatal or non-fatal recurrent venous thromboembolism without increasing the risk of bleeding, and report a number of 33 using 20 mg of rivaroxaban, and a number of 30 using 10 mg of rivaroxaban.

Given the high cost of rivaroxaban, do you think its use for DVT prophylaxis is cost effective?